Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

IMPROVE-PD

Financiado

Cerrado

Identification and Management of Patients at Risk Outcome and Vascular Events...

Identification and Management of Patients at Risk Outcome and Vascular Events in Peritoneal Dialysis Peritoneal dialysis (PD) is an underused life saving renal replacement therapy for end-stage kidney disease. Nevertheless, PD patients remain at high risk for poor outcome, most notably excessive risk of cardiovascular disease. Th... ver más

30/06/2023

CSIC

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 2-3 | 552M€

Fecha límite participación Sin fecha límite de participación.

Ver 23 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-06-30

MSCA-ITN-2018: Innovative Training Networks

I+D

Cerrada hace 7 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

23 Participantes

CSIC

501.81K€ | Lider

Anglian Water Services Limit...

N.D. | Participante

EuroPD e.V.

N.D. | Participante

FUNDACIÓN PARA LA INVESTIGAC...

N.D. | Participante

Proyectos interesantes

EUTRIPD

Medical Technol...

Data Science

3M€ Cerrado

PICKED

Medical Technol...

Data Science

Cerrado

Warrick X1

Medical Technol...

Materials Scien...

3M€ Cerrado

TheraPD

Medical Technol...

Data Science

3M€ Cerrado

DIREKT

Medical Technol...

Data Science

8M€ Cerrado

DECODE-DKD

Medical Technol...

Data Science

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 57 meses Fecha Inicio: 2018-09-13
Fecha Fin: 2023-06-30

Líder del proyecto

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 2-3 | 552M€

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Peritoneal dialysis (PD) is an underused life saving renal replacement therapy for end-stage kidney disease. Nevertheless, PD patients remain at high risk for poor outcome, most notably excessive risk of cardiovascular disease. There is an unmet need for a risk-adjusted individualized PD approach. The IMPROVE-PD consortium provides 15 Early Stage Researchers (ESRs) in 11 partner institutes located in 7 different countries a state-of-the-art, multidisciplinary and intersectoral pan- European training programme including input from academic, clinical and industrial stakeholders. Network-wide and local training activities, individual research projects, intersectoral secondments and short laboratory visits will provide key generic skills and will prepare ESRs for future roles as highly skilled researchers in Europe. Well-phenotyped patient cohorts, and novel experimental models and techniques will be exploited by the ESRs, mentored by an excellent supervisory team, to improve future management of the PD patient at risk. This joint effort encourages productive collaboration between industrial and academic sectors though integrated projects and shared goals. Key findings will be communicated to a broad range of stakeholders through state of the art methods. IMPROVE-PD will give rise to a new generation of experts in PD with outstanding interdisciplinary research skills, intersectoral understanding and with perspective to pursue their careers in this scientific and industrial field. It will enable timely identification of the PD patient at high risk for adverse outcome, develop understanding of underlying pathomechanisms, and within an iterative process between research groups foster the development of innovative approaches to individualized treatment by targeting revealed pathomechanisms. Through these approaches, the ITN will achieve refinement of PD fluids, PD therapy and cardiovascular risk reduction.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores